<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02665221</url>
  </required_header>
  <id_info>
    <org_study_id>15-00173</org_study_id>
    <nct_id>NCT02665221</nct_id>
  </id_info>
  <brief_title>Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY</brief_title>
  <official_title>Single Center, Randomized, Open Label Study in Relapsing MS Patients on PLEGRIDY to Assess Topical Application of Preparation H (Phenylephrine) on Mitigation of Erythema Severity and Size.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this single center, randomized, open label study in relapsing Multiple
      Sclerosis (MS) patients on PLEGRIDY (peginterferon beta-1a) is to assess the effect of
      Preparation H (phenylephrine) Maximum Strength Cream compared to no topical treatment of
      injection site erythema after PLEGRIDY injection.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    It was decided on 9/21/2016 to terminate this study early because LogPad devices the patients
    used to record their injection data was flawed
  </why_stopped>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Erythema Self-Assessment (PSA) Score 6 hr After Application of Preparation H to First Injection Site Erythema Compared to Baseline PSA Score of Injection Site Erythema at Least 2 Hours After PLEGRIDY Injection.</measure>
    <time_frame>6 Hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Width of Injection Site Erythema in Millimeters 6 hr After Application of Preparation H to First Injection Site Erythema Compared to Baseline Width of Injection Site Erythema at Least 2 Hours After Injection.</measure>
    <time_frame>6 Hours</time_frame>
    <description>Study was terminated. No data analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Experiencing Injection Site Reaction Erythema, Itching and Pain.</measure>
    <time_frame>6 Hours</time_frame>
    <description>Study was terminated. No data analyzed. Study was terminated. No data analyzed because the Logpad being used by subjects was flawed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Flu-like Symptom Scale at Last Visit Compared to Base Line.</measure>
    <time_frame>6 Hours</time_frame>
    <description>Study was terminated. No data analyzed because the Logpad being used by subjects was flawed.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Treatment Arm</intervention_name>
    <description>Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Preparation H arm</intervention_name>
    <description>Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A confirmed diagnosis of relapsing multiple sclerosis, as defined by McDonald
             criteria.

          -  Age 18 to 70 years old, inclusive, at the time of informed consent.

          -  Na√Øve to PLEGRIDY or less than or equal to 12 months on PLEGRIDY therapy.

        Exclusion Criteria:

          -  Primary progressive, secondary progressive or progressive relapsing MS.

          -  Concurrent enrollment in any clinical trial of an investigational product.

          -  Known allergy to any interferon or any component of PLEGRIDY (peginterferon beta-1a).

          -  Known allergy to phenylephrine, pramoxane or any component of Preparation H.

          -  History of hypersensitivity or intolerance to naproxen or acetaminophen (Tylenol) that
             would preclude the use of at least 1 of these during the study.

          -  History of inadequate response to subcutaneous interferon beta therapy.

          -  History of human immunodeficiency virus, hepatitis C virus antibody or current
             hepatitis B infection.

          -  History of premalignant and malignant disease including solid tumors and hematologic
             malignancies (except basal cell and squamous cell carcinomas of the skin that have
             been completely excised and are considered cured).

          -  History of any clinically significant cardiac, endocrinologic, hematologic, hepatic,
             immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric,
             and renal, or other major disease, as determined by the Investigator.

          -  History of seizure disorder or unexplained blackouts.

          -  History of suicidal ideation or an episode of clinically severe depression (as
             determined by the Investigator) within 3 months prior to Day 1.

          -  Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g.,
             pneumonia, septicemia), at the discretion of the Investigator, within 3 months prior
             to Day 1.

          -  History of drug or alcohol abuse (as defined by the Investigator) within 6 months
             prior to Day.

          -  Active bacterial or viral infection.

          -  Inability to comply with study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Kalina</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2016</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2016</study_first_posted>
  <results_first_submitted>October 9, 2017</results_first_submitted>
  <results_first_submitted_qc>December 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2018</results_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>erythema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>No Treatment Arm: Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Group</title>
          <description>Topical Preparation H arm: Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>No Treatment Arm: Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.</description>
        </group>
        <group group_id="B2">
          <title>Treatment Group</title>
          <description>Topical Preparation H arm: Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Erythema Self-Assessment (PSA) Score 6 hr After Application of Preparation H to First Injection Site Erythema Compared to Baseline PSA Score of Injection Site Erythema at Least 2 Hours After PLEGRIDY Injection.</title>
        <time_frame>6 Hours</time_frame>
        <population>Study was terminated. Logpad used by subjects was defective and data was not collected. No data analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No Treatment Arm: Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group</title>
            <description>Topical Preparation H arm: Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Erythema Self-Assessment (PSA) Score 6 hr After Application of Preparation H to First Injection Site Erythema Compared to Baseline PSA Score of Injection Site Erythema at Least 2 Hours After PLEGRIDY Injection.</title>
          <population>Study was terminated. Logpad used by subjects was defective and data was not collected. No data analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Width of Injection Site Erythema in Millimeters 6 hr After Application of Preparation H to First Injection Site Erythema Compared to Baseline Width of Injection Site Erythema at Least 2 Hours After Injection.</title>
        <description>Study was terminated. No data analyzed</description>
        <time_frame>6 Hours</time_frame>
        <population>Study was terminated. Logpad used by subjects was defective and data was not collected. No data analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No Treatment Arm: Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group</title>
            <description>Topical Preparation H arm: Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.</description>
          </group>
        </group_list>
        <measure>
          <title>Width of Injection Site Erythema in Millimeters 6 hr After Application of Preparation H to First Injection Site Erythema Compared to Baseline Width of Injection Site Erythema at Least 2 Hours After Injection.</title>
          <description>Study was terminated. No data analyzed</description>
          <population>Study was terminated. Logpad used by subjects was defective and data was not collected. No data analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Experiencing Injection Site Reaction Erythema, Itching and Pain.</title>
        <description>Study was terminated. No data analyzed. Study was terminated. No data analyzed because the Logpad being used by subjects was flawed.</description>
        <time_frame>6 Hours</time_frame>
        <population>Study was terminated. No data analyzed. Study was terminated. No data analyzed because the Logpad being used by subjects was flawed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No Treatment Arm: Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group</title>
            <description>Topical Preparation H arm: Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing Injection Site Reaction Erythema, Itching and Pain.</title>
          <description>Study was terminated. No data analyzed. Study was terminated. No data analyzed because the Logpad being used by subjects was flawed.</description>
          <population>Study was terminated. No data analyzed. Study was terminated. No data analyzed because the Logpad being used by subjects was flawed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Flu-like Symptom Scale at Last Visit Compared to Base Line.</title>
        <description>Study was terminated. No data analyzed because the Logpad being used by subjects was flawed.</description>
        <time_frame>6 Hours</time_frame>
        <population>Study was terminated. Logpad used by subjects was defective and data was not collected. No data analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>No Treatment Arm: Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Group</title>
            <description>Topical Preparation H arm: Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.</description>
          </group>
        </group_list>
        <measure>
          <title>Flu-like Symptom Scale at Last Visit Compared to Base Line.</title>
          <description>Study was terminated. No data analyzed because the Logpad being used by subjects was flawed.</description>
          <population>Study was terminated. Logpad used by subjects was defective and data was not collected. No data analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>No Treatment Arm: Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.</description>
        </group>
        <group group_id="E2">
          <title>Treatment Group</title>
          <description>Topical Preparation H arm: Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shannon Haas</name_or_title>
      <organization>MS Comprehensive Care Center NYU Langone Health</organization>
      <phone>646 501 7504</phone>
      <email>Shannon.Haas@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

